/assets/images/provider/photos/2846725.jpeg)
Experiencing recurrent pregnancy loss (RPL) is heartbreaking and can leave couples feeling frustrated and uncertain about their future chances of parenthood. For those undergoing in vitro fertilization (IVF), advanced diagnostic tools and targeted treatments can improve the odds of a successful pregnancy. Two such approaches gaining attention are Endometrial Receptivity Array (ERA) testing and immune protocol therapies.
Recurrent pregnancy loss is typically defined as two or more consecutive miscarriages. While many causes exist—from chromosomal abnormalities to anatomical issues—some cases remain unexplained despite thorough evaluation.
ERA testing is a genetic test that analyzes the endometrial lining (the uterine lining) to determine the optimal window of implantation. The timing of embryo transfer during IVF is usually based on a standard schedule, but ERA testing personalizes this by identifying when the uterus is most receptive to the embryo.
Benefits:
Some research suggests that immune system imbalances can contribute to recurrent pregnancy loss by causing inflammation or attacking the embryo. Immune protocols may include medications or supplements aimed at modulating immune responses to support implantation and pregnancy maintenance.
Common treatments:
For patients with recurrent pregnancy loss undergoing IVF, combining personalized embryo transfer timing with immune support can optimize conditions for implantation and reduce the chance of miscarriage.
If you’ve experienced recurrent pregnancy loss, University Reproductive Associates can provide comprehensive evaluation and cutting-edge treatments tailored to your needs. Our team will work closely with you to develop a personalized plan incorporating tools like ERA testing and immune protocols when appropriate.
Take the next step toward your family-building goals. Schedule a consultation today with University Reproductive Associates to discuss how advanced IVF strategies can help you achieve a successful pregnancy.